NeoRx is a clinical decision support tool for neonatologists — NeoFax-based dosing with GA, DOL & renal correction, auto-calculated drug volumes, fluid overload prevention in IVF & TPN, and print-ready order sheets. All in one place.
⚕ Important — Clinical Decision Support Only · NeoRx is a calculation aid. Every dose, fluid order, and electrolyte correction generated by this tool must be independently verified and signed by an authorised physician before administration. NeoRx does not replace clinical judgment, direct patient assessment, or institutional protocols. For emergencies, always follow your unit's standing orders. Read full disclaimer →
Designed by a neonatologist for the realities of bedside care in Indian NICUs.
We are currently onboarding hospitals. Contact us to set up access for your team.
Request Access for Your HospitalNeoRx was created out of a simple frustration — the tools available to neonatologists in Indian NICUs were either too generic, too expensive, or simply not built for how we actually work.
Manual drug dose calculation in a NICU is error-prone and time-consuming. A nurse or resident calculates a weight-based dose on a phone calculator, cross-checks NeoFax, adjusts for gestational age — and does this for every drug, every shift, for every patient.
Medication errors in neonatal care are one of the leading causes of preventable harm. Preterm infants have almost no physiological reserve — a tenfold dosing error that an adult might tolerate can be fatal in a 700-gram baby.
NeoRx was built to eliminate that manual calculation step entirely, replacing it with a clinically validated, protocol-based engine that produces correct doses the first time.
NeoRx was designed and built by a practising neonatologist with direct experience of NICU workflows in Indian private hospitals. Every drug, every dosing rule, every preparation instruction has been personally reviewed against published guidelines.
The clinical validation is ongoing — the error flagging feature is not just a bug report system. It is a pharmacovigilance mechanism that creates a continuous feedback loop between bedside use and database accuracy.
All drug dosing in NeoRx is based on the following primary sources. No dose is assumed — each has been individually cross-checked:
National Neonatology Forum of India — primary reference for Indian NICU practice
All India Institute of Medical Sciences neonatal drug protocols
Indian Academy of Pediatrics — antimicrobial and supportive care guidelines
Thomson Reuters NeoFax — international neonatal drug reference, used for cross-validation
Indian-specific dosing: 25,000–40,000 U/kg based on local resistance patterns and published data
AIIMS/NNF electrolyte correction protocols — TBW factors, correction rates, monitoring schedules
NeoRx is a clinical decision support tool, not a prescribing system. Every order it generates requires review, verification, and signature by an authorised physician before administration.
It does not replace clinical judgment. A calculated dose that appears inconsistent with the patient's clinical state should always be questioned. The error flagging system exists precisely for this reason.
For hospital onboarding, clinical feedback, or drug database queries — please use the contact form or email directly.
Every drug dose, interval, and preparation instruction in NeoRx is derived from published guidelines and cross-validated against multiple sources. This page lists the primary references used.
National Neonatology Forum of India. Primary reference for drug dosing in Indian NICUs. Covers gestational age-based dosing, postnatal age adjustments, and Indian pharmacokinetic data.
NNF IndiaAll India Institute of Medical Sciences — departmental neonatal drug protocols. Used for electrolyte correction equations (TBW factors, correction rates), antibiotic dosing in extreme prematurity, and TPN calculations.
AIIMSIndian Academy of Pediatrics — antimicrobial stewardship guidelines for neonates. Used for empirical antibiotic selection, duration of therapy, and escalation criteria.
IAPGuidelines for amino acid and lipid dosing, GIR targets, and TPN monitoring in preterm and term neonates.
NNF IndiaInternational standard neonatal drug reference. Used as cross-validation for all doses in NeoRx. Where NeoFax and NNF/AIIMS differ, the Indian guideline is preferred with the discrepancy documented.
NeoFaxPediatric & Neonatal Dosage Handbook. Used for preparation instructions, compatibility data, and infusion rate guidelines.
ReferenceEuropean Society for Paediatric Gastroenterology — TPN macronutrient and micronutrient guidelines. Used for AA/lipid dosing ranges and GIR targets.
InternationalIndian-specific colistimethate sodium dosing at 25,000–40,000 U/kg based on published Indian pharmacokinetic studies and local antimicrobial resistance patterns. Differs from international guidelines due to endemic resistance profiles.
IAP / Indian DataTBW correction factors: preterm 0.7, term 0.6. Maximum correction rates: Na +8 mmol/L/24h, K 0.3–0.5 mEq/kg/hr. Hypocalcaemia thresholds: preterm Ca <7.0, term <8.0 mg/dL.
AIIMS/NNFGentamicin and amikacin extended-interval dosing based on gestational and postnatal age. Intervals: q24h–q48h based on renal maturation. NNF/AIIMS consensus.
NNF IndiaAll 56 drugs in NeoRx have been individually cross-checked against NNF, AIIMS, and NeoFax during a structured pre-pilot audit. Discrepancies were resolved by clinical review. Audit log maintained internally.
Internal AuditNeoRx includes a built-in error flagging mechanism on every calculated order. All flags are reviewed by the clinical team and corrections applied to the database. This constitutes an ongoing post-market surveillance mechanism.
PharmacovigilanceNeoRx is a clinical decision support tool. All calculated doses are derived from published guidelines but must be verified by an authorised physician before administration. Drug doses may need to be individualised based on patient-specific clinical factors not captured by a calculator. The references listed here represent the primary sources used — clinicians are encouraged to consult primary literature for unusual clinical scenarios. NeoRx does not replace clinical judgment.
We are currently onboarding hospitals. Fill the form and we will get back to you within 24 hours.
NeoRx is clinically validated and in active use at a Level III private NICU. We are looking for partner hospitals who want to reduce medication calculation errors and improve order sheet quality.
Subscription-based pricing applies per hospital unit — not per user. Nominal setup and onboarding charges apply. Contact us for a pricing discussion specific to your hospital size and NICU level.
We also welcome clinical feedback, drug database queries, and collaboration from neonatologists who want to contribute to the reference database.
This page explains how NeoRx handles your data, the limitations of this tool, and the terms under which it may be used.
NeoRx is a clinical decision support tool. It is designed exclusively for use by trained medical professionals — neonatologists, paediatricians, and authorised clinical staff — as a calculation aid.
Every dose, fluid order, electrolyte correction, and preparation instruction generated by NeoRx must be independently verified and signed by an authorised physician before it is administered to any patient.
NeoRx does not replace clinical judgment. A calculated dose that appears inconsistent with the patient's clinical state must always be questioned. The treating physician bears full clinical and legal responsibility for all orders administered.
Drug doses may require individualisation based on patient-specific factors — organ function, concurrent medications, clinical trajectory — that are not and cannot be fully captured by a calculator.
In any emergency, follow your unit's established emergency protocols. Do not rely solely on any software tool in a critical situation.
NeoRx is not approved for use by non-clinical personnel without direct physician supervision. It is not intended for patient self-use or for use outside a clinical setting.
All drug dosing algorithms are based on published Indian and international guidelines (NNF, AIIMS, IAP, NeoFax). NeoRx makes no claim of endorsement or affiliation with these organisations. The reference to these guidelines indicates only the source material used in building the dosing database. Guidelines are updated periodically — clinicians should verify that NeoRx reflects the most current version of any protocol.
NeoRx is currently in active clinical use at a Level III NICU in India as part of a structured pilot evaluation. Software that provides clinical decision support is subject to classification under the Medical Devices Rules, 2017 (India) and may require registration with the Central Drugs Standard Control Organisation (CDSCO) prior to broad commercial deployment.
NeoRx is being evaluated for CDSCO Class A registration. Users in institutional settings are advised to confirm with their hospital administration that use of clinical decision support software is consistent with their institutional policies and accreditation requirements.
NeoRx takes data privacy seriously. The following describes what is and is not collected:
Patient names, MRN, date of birth, or any personally identifiable patient information. NeoRx never stores patient data.
Physician identity or credentials. The calculator functions without any login or user identification.
Name, designation, hospital name, city, email, phone — only when you voluntarily submit the contact form.
Drug name, dose, error type, and reporter name when you voluntarily submit an error flag. No patient data.
Contact form data is transmitted via Formspree (formspree.io) to our administrative email. This data is used only to respond to your enquiry and set up hospital access. It is not shared with third parties, sold, or used for marketing purposes.
Error flag data is transmitted via Formspree to our clinical review team. This data is used solely to review and correct the drug dosing database. Reporter name is optional and used only for follow-up if clarification is needed.
Website analytics — NeoRx may use Google Analytics to collect anonymised usage statistics (pages visited, session duration, device type). No personally identifiable information is collected through analytics. You may opt out by using a browser extension that blocks Google Analytics.
Under the Digital Personal Data Protection Act, 2023 (India), you have the right to access, correct, or request deletion of your personal data submitted through our contact form.
To exercise these rights, contact us at neorxadmin@gmail.com. We will respond within 7 working days. Contact form data is retained for a maximum of 2 years or until you request deletion, whichever is earlier.
The NeoRx name, logo, dosing algorithms, software, and website content are the intellectual property of the NeoRx development team. Unauthorised reproduction, redistribution, reverse engineering, or commercial use of any part of NeoRx is prohibited.
References to NNF, AIIMS, IAP, and NeoFax indicate source material only. NeoRx is not affiliated with, endorsed by, or a product of any of these organisations.
Last updated: March 2026